ArticleIntensive care medicine experimental2025
Slow releasing sulphide donor GYY4137 protects mice against ventilator-induced lung injury.
Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hydrogen sulfide inhalation induces changes in body physiology and lung gene expression in mice.Scientific reports · 2026Article
- Therapeutic Potential of GYY4137 in Reducing Oxidative Stress and Mortality in Experimental Decompression Sickness.Scientific reports · 2026Article
- The molecular mechanisms of gas signaling molecules in bronchopulmonary dysplasia related lung injury.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCyclic stretching of the lung during mechanical ventilation induces inflammation that contributes to the development of ventilator induced lung injury. Hydrogen sulphide (H
methodsAnaesthetised male C57BL/6 J mice were pretreated with an intraperitoneal injection of GYY4137 (50 mg/kg, n = 14) or an equivalent volume of phosphate-buffered saline (controls, n = 13) and were then subjected to high tidal volume ventilation (V
resultsGYY4137 pretreatment led to a notable 50% increase in survival rates compared to controls (p = 0.0025). It also improved arterial oxygenation after high V
conclusionsIn this mouse model of VILI, pretreatment with GYY4137 showed protective effects. GYY4137 significantly improved survival. It also improved arterial blood oxygenation and dynamic respiratory system compliance, and mitigated the development of lung oedema and inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.